Integrated Solutions. Proven Performance. Reliable Results.
Customer Perspectives
“Thanks to our partnership with Leica, we have access to instruments of the highest caliber. The whole approach is about the quality, traceability, and connectivity… It's a base to work on innovation and development relying on the know-how of the pathologist. We also want to develop other technologies associated with this basis. So, it can be digital pathology technologies based on artificial intelligence.”
Translated from source language.
Dr. Eric Peltier
Président Directeur Général - PRAXEA-DIAGNOSTICS
"Leica Biosystems products are reliable and high quality, and the company is realistic about what's required to transform traditional pathology to a digital, connected practice. I know I can count on them and trust they will be there to support me now and well into the future."
Translated from source language.
Dr. Sylvia L. Asa, MD, PhD
Consultant in Endocrine Pathology, University Hospitals Cleveland Medical Center
News & Promotions
On-Demand Webinar
AI-Powered QC Where You Need It: Finding Needles in the Haystack
Learn how Leica Biosystems' Aperio iQC software detects artifacts early in the digital pathology workflow, surfaces results in a centralized dashboard, alerts the laboratory via the scanner console, and supports faster, more consistent quality control.
For Research Use Only, Not for Use in Diagnostic Procedures.
Transforming Pathology Services at Pathology & Cytology Laboratories, Kentucky
Read how Kentucky Pathology & Cytology Laboratories (P&C) unlocked exceptional productivity gains, increased their diagnostic capacity, and reduced diagnostic turnaround times for patients by embracing Universal Access workflows and innovations.
For In Vitro Diagnostic Use.
Product Launch
Introducing HER2 (BMA) primary antibody: reproducible HER2 staining through the BOND system
A new recombinant, ready-to-use Class I IVD primary antibody for automated HER2 IHC, engineered for reproducible staining and reflecting Leica Biosystems’ continued commitment to expanding its clinical antibody portfolio.
For In Vitro Diagnostic Use.
